Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab -paclitaxel plus gemcitabine: implication of inflammation-based scores
Conclusion Among the inflammation based prognostic scores, mGPS was a reliable prognostic indicator that could stratify survival outcomes in patients with recurrent or mPC who received AG as first-line chemotherapy.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Investigational New Drugs | Liver | Pancreas | Pancreatic Cancer | Urology & Nephrology